AbbVie has become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray of its kind this morning. The company, which is among the largest pharmaceutical firms in the world, announced a collaboration and option-to-license agreement with the privately held psychedelic drug developer Gilgamesh Pharmaceuticals.
